Clinical Trials on Mature B-cell Non-Hodgkin Lymphoma

Total 6113 results

Juno Therapeutics, a Subsidiary of Celgene
Bristol-Myers Squibb

Completed

A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)

Neoplasms | Neoplasms by Histologic Type | Lymphoma | Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Lymphoproliferative Disorders | Lymphatic Diseases | Immunoproliferative Disorders | Lymphoma, Non-Hodgkin | Immune System Disorder

United States
The Netherlands Cancer Institute
Dutch Cancer Society

Completed

To Decrease Fatigue With Light Therapy (SPARKLE)

Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma

Netherlands
The First Affiliated Hospital of Soochow University

Recruiting

Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

Non-GCB/ABC Diffuse Large B-Cell Lymphoma

China
SWOG Cancer Research Network
National Cancer Institute (NCI); Incyte Corporation; Ipsen; BeiGene

Recruiting

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma | Grade 3b Follicular Lymphoma | Transformed Non-Hodgkin Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

United States
Kite, A Gilead Company

Completed

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1)

Relapsed Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B Cell Lymphoma (DLBCL) | Transformed Follicular Lymphoma (TFL) | Primary Mediastinal B-cell Lymphoma (PMBCL) | High Grade B-cell Lymphoma (HGBCL)

United States, Netherlands, Canada, France, Germany, Israel
Pinze Lifetechnology Co. Ltd.
Chinese Academy of Sciences; Navy General Hospital, Beijing

Unknown

Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma

B-cell Lymphoma | B-cell Acute Lymphoblastic Leukemia

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma

Refractory Central Nervous System Lymphoma | Central Nervous System B-Cell Non-Hodgkin Lymphoma | Recurrent Central Nervous System Lymphoma

United States
Peking University People's Hospital

Not yet recruiting

CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma

T-cell Non-Hodgkin's Lymphoma
C. Babis Andreadis
University of California, Davis

Recruiting

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

Follicular Lymphoma | Burkitt Lymphoma | Mantle Cell Lymphoma | Lymphoplasmacytic Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Transformed Lymphoma

United States
University Hospital, Limoges

Recruiting

Exosomes and Immunotherapy in Non-Hodgkin B-cell Lymphomas (ExoReBLy)

Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL)

France
The First Affiliated Hospital of Xiamen University
The First Affiliated Hospital with Nanjing Medical University; Shanxi Province... and other collaborators

Recruiting

Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma

Follicular Lymphoma | Relapsed Non-Hodgkin Lymphoma | Refractory B-Cell Lymphoma

China
Medical College of Wisconsin
Midwest Athletes Against Childhood Cancer

Not yet recruiting

CD30biAb-AATC for CD30+ Malignancies

Lymphoma | Leukemia | Hodgkin Disease | CD30-Positive Diffuse Large B-Cell Lymphoma | CD30+ Anaplastic Large Cell Lymphoma | CD30+ Pleomorphic Large T-Cell Cutaneous Lymphoma | CD30+ Immunoblastic Large T-Cell Cutaneous Lymphoma

United States
University of Maryland, Baltimore
University of Maryland Greenebaum Cancer Center

Completed

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Lymphoma | Leukemia

United States
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)

Terminated

Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Lymphoma | Leukemia

United States
National Cancer Institute (NCI)

Withdrawn

BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Lymphoma | Leukemia

United States
Columbia University
Bayer

Withdrawn

Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma

Lymphoma, T-Cell
National Cancer Institute (NCI)

Terminated

CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Hodgkin Lymphoma | Refractory Chronic Lymphocytic Leukemia

United States
National Cancer Institute (NCI)

Completed

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma | Refractory Small Lymphocytic Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular... and other conditions

United States
The First Affiliated Hospital with Nanjing Medical...

Unknown

XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects

Lymphoma, B-Cell | Leukemia, B-cell

China
National Cancer Institute (NCI)

Completed

Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma

Anaplastic Large Cell Lymphoma | Recurrent Adult Non-Hodgkin Lymphoma | Angioimmunoblastic T-Cell Lymphoma | Hepatosplenic T-Cell Lymphoma | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Recurrent Adult T-Cell Leukemia/Lymphoma | Adult Nasal Type Extranodal NK/T-Cell Lymphoma

United States, Canada
Juno Therapeutics, a Subsidiary of Celgene

Terminated

Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product

Follicular Lymphoma | Multiple Myeloma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma

United States
National Cancer Institute (NCI)

Completed

T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies

Lymphoma, B-Cell | Lymphoma, Non-hodgkins

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Intra-Osseous Co-Transplant of UCB and hMSC

Myelodysplastic Syndromes | Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Myelofibrosis | Acute Lymphoblastic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Refractory Chronic Lymphocytic Leukemia | Refractory Non-Hodgkin Lymphoma | Lymphoid Malignancies | Relapsed Non-Hodgkin Lymphoma and other conditions

United States
Bristol-Myers Squibb

Completed

Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

Renal Cell Carcinoma | Non-hodgkin's Lymphoma

United States
University of Utah

Recruiting

Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies (PRODIGY)

Acute Lymphoblastic Leukemia | Diffuse Large B Cell Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Richter Syndrome and other conditions

United States
Ohio State University Comprehensive Cancer Center

Recruiting

Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type

United States
Novartis Pharmaceuticals

Recruiting

Study of Out of Specification for Tisagenlecleucel

Diffuse Large B-cell Lymphoma | B-cell Acute Lymphoblastic Leukemia

Japan, Canada
Children's Hospital Medical Center, Cincinnati

Withdrawn

Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma

Lymphoma, B-Cell | Leukemia, B-cell

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma

HIV Infection | Recurrent Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | AIDS-Related Non-Hodgkin Lymphoma | AIDS-Related Hodgkin Lymphoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Suspended

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent Breast Carcinoma | Recurrent Mycosis Fungoides | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage IV Breast Cancer AJCC v6 and v7 | Breast Adenocarcinoma and other conditions

United States
Schrödinger, Inc.

Recruiting

Study of SGR-1505 in Mature B-Cell Neoplasms

Follicular Lymphoma | Splenic Marginal Zone Lymphoma | Burkitt Lymphoma | Plasmablastic Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Non Hodgkin Lymphoma | Primary Effusion Lymphoma | DLBCL | High-grade B-cell Lymphoma | Primary Mediastinal... and other conditions

United States, Moldova, Republic of
National Cancer Institute (NCI)

Completed

Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma

United States
University of Washington
Bayer

Terminated

Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma

Non-Hodgkin's Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Follicular Lymphoma | Grade 3b Follicular Lymphoma

United States
National Cancer Institute (NCI)

Terminated

O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma

Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma | Stage I Cutaneous T-cell Non-Hodgkin Lymphoma | Stage II Cutaneous T-cell Non-Hodgkin Lymphoma

United States
Chongqing Precision Biotech Co., Ltd

Recruiting

Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Lymphoma, B-Cell | Leukemia, B-cell

China
Peking Union Medical College Hospital
Peking University First Hospital; Chinese PLA General Hospital; Peking University... and other collaborators

Recruiting

Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma

T Cell Non-Hodgkin's Lymphoma

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ultra Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT Lymphoma

Gastric Mucosa-Associated Lymphoid Tissue Lymphoma

United States
Aegera Therapeutics
The Leukemia and Lymphoma Society

Terminated

A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas

Lymphoma, B-Cell | Leukemia, Lymphocytic, Chronic, B-Cell

Canada, United States
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Active, not recruiting

A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

China
GWT-TUD GmbH

Completed

ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy

Lymphoma, B-Cell | Lymphoma, T-Cell | Aggressive Non-hodgkin Lymphoma (aNHL)

Germany
New York Medical College
Roswell Park Cancer Institute

Recruiting

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL (O-ICE)

Diffuse Large B-Cell Lymphoma | Burkitt Lymphoma | Non-Hodgkin Lymphoma | Primary Mediastinal B-cell Lymphoma | CD20+ Lymphoblastic Lymphoma | Follicular Lymphoma, Grade III

United States
Weprom
Takeda; SIVAN Innovation

Terminated

Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or Partial Response

Lymphoma, Large B-Cell, Diffuse | Lymphoma, T-Cell | Lymphoma, Hodgkin

France
Ruijin Hospital

Recruiting

Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL

Primary Mediastinal Large B Cell Lymphoma | EBV-Positive DLBCL, Nos

China
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic... and other conditions

United States
National Taiwan University Hospital

Recruiting

A Mixed Methods Study of Nutrition Practice in Cancer Care on Non-Hodgkin Lymphoma Population

Lymphoma, B-Cell

Taiwan
University of Washington
National Cancer Institute (NCI)

Completed

Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Zhejiang DTRM Biopharma

Completed

Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas

Chronic Lymphocytic Leukemia | B-Cell Lymphoma

United States
Atara Biotherapeutics

Recruiting

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

High-grade B-cell Lymphoma | MCL | Diffuse Large B-cell Lymphoma (DLBCL) | Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | DLBCL/High-grade B-cell Lymphoma With MYC and BCL2 Rearrangements | Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma | LBCL With IRF4 Rearrangement | High-grade B-cell... and other conditions

United States
Sutro Biopharma, Inc.

Completed

Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Follicular Lymphoma | B-cell Lymphoma | Multiple Myeloma | Mantle Cell Lymphoma | Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | Indolent Lymphoma | B Cells--Tumors

United States

Clinical Trials on Mature B-cell Non-Hodgkin Lymphoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations